

U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.

ATTY. DOCKET NO. 210121.491°C7

APPLICATION NO. 10/010.742

Davin C. Dillon et al. Davin C. Dillon et al. Dilling date November 30, 2001 DCUMENTS NAME DOCUMENTS COUNTRY	CLASS 435	UP ART UNIT 637 SUBCLASS 69.1	FILING IF APPRO	DATE OPRIATE				
November 30, 2001 OCUMENTS NAME DOCUMENTS	CLASS	637 SUBCLASS						
NAME DOCUMENTS	 							
DOCUMENTS	 							
	435	69.1						
		·						
COUNTRY								
			TRANSI YES	LATION NO				
		·						

			·					
uthor, Title, Date, Pertinent Pag	es, Etc.)							
natomy: correlation of the novel gene produc								
Diatchenko et al., "Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries," <i>Proc. Natl. Acad. Sci. USA 93</i> :6025-6030, June 1996.								
Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system expression of CD8α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.								
Hedblom and Kirkness, "A novel class of GABA _A receptor subunit in tissues of the reproductive system," <i>The Journal of Biological Chemistry</i> 272(24):15346-15350, June 13, 1997.								
Lee et al., "Positive selection of candidate tumor-suppressor genes by subtractive hybridization," <i>Proc. Natl. Acad. Sci. USA 88</i> :2825-2829, April 1991.								
Porter-Jordan and Lippman, "Overview of the biologic markers of breast cancer," <i>Breast Cancer</i> 8(1):73-100, February 1994.								
DATE CONSIDERED	10/71	107						
the state of the s	tive hybridization: A c cDNA probes and enotype by a novel coved interleukin-4-dependent of GABA _A receptor iological Chemistry atte tumor-suppressor (ISA 88:2825-2829, A c of the biologic market	tive hybridization: A method c cDNA probes and libraries, enotype by a novel cDNA libraries and interleukin-4-dependent coof GABA _A receptor subunit in iological Chemistry 272(24): attentional terms of the biologic markers of broad of the biologic markers of the biologic markers of broad of the biologic markers of the biologic markers of the biologic markers o	tive hybridization: A method for generate c cDNA probes and libraries," <i>Proc. Nat.</i> enotype by a novel cDNA library subtractived interleukin-4-dependent cell line," <i>B</i> of GABA _A receptor subunit in tissues of <i>iological Chemistry 272</i> (24):15346-1533 atte tumor-suppressor genes by subtractive <i>ISA 88</i> :2825-2829, April 1991.	enotype by a novel cDNA library subtraction sylved interleukin-4-dependent cell line," <i>Blood</i> of GABA _A receptor subunit in tissues of the <i>iological Chemistry</i> 272(24):15346-15350, Junate tumor-suppressor genes by subtractive <i>ISA</i> 88:2825-2829, April 1991.				

PRINCE PROPERTY AND TRADEMARK OFFICE INFORMATION AND TRADEMARK OFFICE PATENT DOCUMENTS U.S. PATENT DOCUMENTS PATENT DOCUMENTS PATENT DOCUMENTS PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS PATENT DOCUMENTS PATENT DOCUMENTS PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS PATENT DOCUMENTS PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FUNCTION PATENT DO				Ŋ					Sheet _2	of <u>2</u>				
INFORMER DISCLOSURE STATEMENT (Use several sheets (frecessory) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS CLASS SURCLASS FILING DATE NAME CLASS SURCLASS FILING DATE PAPPOPEIATE		JAN	* '440Z \(\text{2}\)											
FILING DATE NOVEMBER 30, 2001 GROUP ART UNIT 16 3 7 7	A PAGE OF THE PAGE													
U.S. PATENT DOCUMENTS CLASS SUBCLASS FILING DATE	INFO	ORM			ENT	Davin C. Dillon et al.								
U.S. PATENT DOCUMENTS SUBCLASS FEINC DATE NAME CLASS SUBCLASS FEINC DATE FAPROPRIATE	(Use several sheets if necessary)					G	ROUP ART UNIT							
FEXAMENER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILNO DATE FOREIGN PATENT DOCUMENTS TRANSLATION TRANSLATION TYPE NO BB DOCUMENT NUMBER DATE COUNTRY TRANSLATION TYPE NO BB BC DATE COUNTRY TRANSLATION TYPE NO BB BC DATE COUNTRY TRANSLATION TYPE NO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BI BI BI BI BK BL DATE CONSIDERED						November 30, 2001		163F						
BA SIBLEAS IF APPROPRIATE				U.S.	PATENT	DOCUMENTS	. .							
FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY TRANSLATION YES NO			DOCUMENT NUMBER	DATE		NAME CLASS SUBC								
BB BC BD BC BB BF		ВА												
BB BC BC BD BE BF Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BH BI BI BL				FOREI	GN PATE	NT DOCUMENTS								
BB BC BD BE BF SCHOME and Scholar Author, Title, Date, Perlinent Pages, Etc.) OTHER PRIOR ART (Including Author, Title, Date, Perlinent Pages, Etc.) Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BH BI BI BK BL ENAMINED														
BD BE BF OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BH BI BI BI BL EVAMPER		BB ⁻							123	110				
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BI BI BI BI BI BI BI BI BI B		BC			· ·		·	W						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BH BI BI BI BK BL DATE CONSIDERED		BD												
OTHER PRIOR ART (Including Author, Title, Date, Pertiment Pages, Etc.) BG Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BH BI BJ BI BK		BE												
Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BI BI BI BI BL EVAMINED		BF												
Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BI BI BI BI BI BI BI BI BL BATE CONSIDERED		l	ОТНЕ	CR PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges. Etc.)			1				
immunotherapy of breast cancer," Breast Cancer Research and Treatment 38(1):27-39, 1996. BH BI BJ BK BL DATE CONSIDERED	-													
BI B		BG							1.27.20	.				
BI BJ BK BK	1.7			ipy of oreast	cancer, b	reasi Cancer Research	ana ir	ештені 36(1).21-3	, 				
BI BJ BK BK		BH												
BK BK BL DATE CONCIDENCE		БП												
BK BK BL DATE CONCIDENCE	:													
BK BK BL DATE CONCIDENCE		Di												
BK BK BL DATE CONSIDERED		Di												
BK BL DATE CONSIDERED														
BL BL DATE CONSIDERED		BJ												
BL BL DATE CONSIDERED														
BL DATE CONSIDERED														
BL DATE CONSIDERED		BK												
BL DATE CONSIDERED														
EVAMINED DATE CONSIDERED							·							
EVAMINED DATE CONSIDERED		BL					=======================================							
EVAMINED DATE CONCIDENCE														
EXAMINER Textra Strelection DATE CONSIDERED 10/7/03														
	EXAMINE	ER	Tenera Sta	relecti	CM	DATE CONSIDERED	-10	17103		-				

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV34701162 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO (REV.7-80) PATENT AND TRADEMARK OFFICE 210121.491C7 **APPLICANTS SUPPLEMENTAL** Davin C. Dillon et al. NEORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) FILING DATE November 30, 2001 U.S. PATENT DOCUMENTS FILING DATE DOCUMENT NUMBER DATE CLASS SUBCLASS NAME IF APPROPRIATE AA AB AC ΑD ΑE ΑF FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION DATE COUNTRY NUMBER AG WO 01/51638 07/19/01 **WIPO** 15 WO 01/51628 07/19/01 **WIPO** ΑH ΑI ΑJ ΑK OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) AL^{i} GenBank Database, Accession No. AJ131016, February 4, 2000. GenBank Database, Accession No. AL135960, February 3, 2000. ΑM GenBank Database, Accession No. AL356793, November 29, 2001. ΑÑ Genseq Database (Thomason Derwent), Accession No. AAL08649, December 7, 2001. ΑĊ Genseq Database (Thomason Derwent), Accession No. AAL18673, December 7, 2001. AP Genseq Database (Thomason Derwent), Accession No. AAL23934, December 7, 2001. AQ Genseq Database (Thomason Derwent), Accession No. AAL24582, December 7, 2001. **EXAMINER DATE CONSIDERED** Sinelection * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

\392752